Lymphoma, T-Cell: all 723 studies
Page 5 of 8. Open to participants first (121), then studies with results posted, then the rest; newest registration first within each.
- PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell LymphomaStatus unknownNCT04038411Phase 4
- CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)WithdrawnNCT04021082Phase 2/3
- Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte MalignanciesStatus unknownNCT04008394Phase 1
- CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic LeukemiaStatus unknownNCT04004637Phase 1
- A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory MalignanciesWithdrawnNCT03999658Phase 2
- Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell LymphomaStatus unknownNCT03952572Phase 3
- A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell LymphomaActive, not recruitingNCT03952078Phase 1
- Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell LymphomaCompletedNCT03936452Phase 2
- Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and LymphomasWithdrawnNCT03925428Phase 1
- Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory LymphomaStatus unknownNCT03921879Phase 1
- IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell LymphomaCompletedNCT03902184Phase 2
- Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell LymphomaStatus unknownNCT03853044Phase 2
- PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR StudyTerminatedNCT03837457Phase 2
- A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)CompletedNCT03833180Phase 1
- Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis FungoidesTerminatedNCT03789864Not applicable
- A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell LymphomaStatus unknownNCT03776279Phase 2
- Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast CancerStatus unknownNCT03775525Phase 1
- ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell LymphomaCompletedNCT03742921
- Study Of Intratumoral G100 In Cutaneous T Cell LymphomaWithdrawnNCT03742804Phase 2
- Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell LymphomaStatus unknownNCT03730740Phase 2
- PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell LymphomaStatus unknownNCT03701022Phase 2
- Allo-HSCT as First-line Consolidation in High-risk PTCLStatus unknownNCT03672084
- VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma PatientsStatus unknownNCT03671850Phase 2
- AEDV Registry of Primary Cutaneous LymphomaStatus unknownNCT03646422
- Treatment of Newly Diagnosed Peripheral T-cell LymphomaStatus unknownNCT03631862Phase 4
- Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell LymphomaStatus unknownNCT03630731Phase 2
- SIMPLE Chemotherapy for NK Lymphoma/LeukaemiaStatus unknownNCT03623087Phase 3
- Anlotinib for Advanced and Refractory Natural Killer /T-cell LymphomaCompletedNCT03618238Phase 2
- Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma PatientsStatus unknownNCT03617432Phase 2
- Pacritinib in Relapsed/Refractory Lymphoproliferative DisordersTerminatedNCT03601819Phase 1
- Tofacitinib Combined With Chidamide in R/R ENKTCLStatus unknownNCT03598959Phase 2
- Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell LymphomasWithdrawnNCT03586024Phase 1/2
- Study of Photopheresis in the Treatment of Erythrodermic MF and SSWithdrawnNCT03563040Phase 2
- PLM60 for Peripheral T Cell Lymphoma (PTCL)WithdrawnNCT03553914Phase 1/2
- Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell LymphomaStatus unknownNCT03553537Phase 3
- Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell LymphomaTerminatedNCT03552692Phase 2
- Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)Status unknownNCT03502629Phase 2
- Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With GemcitabineCompletedNCT03496779Phase 2
- Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell LymphomaCompletedNCT03487133Phase 2
- Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]Status unknownNCT03439501Phase 2
- Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast CancerTerminatedNCT03432741Phase 1
- A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)Active, not recruitingNCT03385226Phase 2
- Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell LymphomasWithdrawnNCT03373305Phase 1
- SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell LymphomaStatus unknownNCT03363555Phase 2
- PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)TerminatedNCT03357224Phase 2
- Pralatrexate for Relapsed or Refractory Peripheral T-cell LymphomaCompletedNCT03356678
- Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCLWithdrawnNCT03355768Phase 3
- Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)Status unknownNCT03321890Phase 2
- Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin LymphomaCompletedNCT03302728Phase 1
- Minimal Residual Disease in Peripheral T-cell LymphomaCompletedNCT03297697
- Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide)Status unknownNCT03273452Phase 2
- Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma)Status unknownNCT03268889Not applicable
- Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological MalignanciesCompletedNCT03263637Phase 1
- Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell TransplantCompletedNCT03259503Phase 1
- B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell LymphomaCompletedNCT03246750Phase 1/2
- Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCLActive, not recruitingNCT03240211Phase 1
- Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell LymphomaWithdrawnNCT03235869Early Phase 1
- CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.CompletedNCT03217643Phase 2
- Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell LymphomaCompletedNCT03212937Phase 1
- T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas PatientsStatus unknownNCT03207789
- Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell LymphomasWithdrawnNCT03205891Phase 1
- Mindfulness Interventions and Cutaneous T Cell Lymphoma (CTCL)TerminatedNCT03174808Not applicable
- Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for LymphomaStatus unknownNCT03161223Phase 1/2
- GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell LymphomaStatus unknownNCT03154918Phase 2
- A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior TherapyStatus unknownNCT03150602Phase 4
- Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma PatientsCompletedNCT03141203Phase 1/2
- CTCL Directed TherapyStatus unknownNCT03116659Early Phase 1
- Treatment of Relapsed or Refractory Natural Killer/T Cell LymphomaStatus unknownNCT03107962Phase 2
- Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL PatientsStatus unknownNCT03079947
- Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL PatientsCompletedNCT03079544
- Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell LymphomasStatus unknownNCT03071822Phase 4
- Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell LymphomaStatus unknownNCT03054532Phase 2
- Copanlisib and Gemcitabine in Relapsed/Refractory PTCLCompletedNCT03052933Phase 1/2
- 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell LymphomaStatus unknownNCT03051581Not applicable
- Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell LymphomaStatus unknownNCT03051568Not applicable
- 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell LymphomaStatus unknownNCT03051555Not applicable
- Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell LymphomaStatus unknownNCT03051542Not applicable
- Risk Stratification of Nodal PTCLCompletedNCT03040206
- Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma PatientsStatus unknownNCT03023358Phase 3
- The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of LymphomasStatus unknownNCT03000738
- Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell LymphomaStatus unknownNCT02987244Phase 1/2
- Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersActive, not recruitingNCT02978625Phase 2
- Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)CompletedNCT02953301Phase 2
- Chidamide for Refractory/Relapsed Peripheral T Cell LymphomaStatus unknownNCT02944812Phase 2
- Chidamide Combined With Cyclophosphamide, Prednisone, Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell LymphomaStatus unknownNCT02879526Phase 2
- Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell LymphomasWithdrawnNCT02875002Phase 1
- Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell LymphomaStatus unknownNCT02856997Phase 2
- Study of Apatinib and MASCT in Patients With Advanced Solid TumorsStatus unknownNCT02844881Phase 1/2
- Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell LymphomaCompletedNCT02825147Phase 2
- Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCLTerminatedNCT02811783Phase 3
- Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma PatientsCompletedNCT02809573Phase 1
- Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell LymphomaTerminatedNCT02808091Phase 2
- A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell LymphomasCompletedNCT02788916
- Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell LymphomasCompletedNCT02783625Phase 1
- MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell LymphomaCompletedNCT02764281Not applicable
- Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell LymphomaStatus unknownNCT02753543Phase 2
- CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and LymphomaStatus unknownNCT02742727Phase 1/2
- GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell LymphomaCompletedNCT02733458Not applicable
- Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry StudyCompletedNCT02691351
- Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin LymphomaCompletedNCT02652715Not applicable